Valuation: Sanofi

Market Cap 90.99B 104B 83.62B 77.94B 148B 9,910B 150B 1,004B 390B 4,871B 391B 382B 16,786B P/E 2026 *
11.4x
P/E 2027 * 10.4x
Enterprise Value 101B 115B 92.51B 86.23B 164B 10,964B 166B 1,111B 432B 5,389B 432B 423B 18,571B EV / Sales 2026 *
2.14x
EV / Sales 2027 * 1.93x
Free-Float
89%
Yield 2026 *
5.61%
Yield 2027 * 5.95%
1 week+2.70%
Current month+0.88%
1 month+0.88%
3 months-10.24%
6 months-8.80%
Current year-9.52%
1 week 11.3
Extreme 11.3
11.5
1 month 10.9
Extreme 10.9
11.9
Current year 10.9
Extreme 10.9
13
1 year 10.9
Extreme 10.9
13.32
3 years 10.9
Extreme 10.9
13.32
5 years 10.9
Extreme 10.9
13.32
10 years 10.9
Extreme 10.9
13.32
Manager TitleAgeSince
Chief Executive Officer 65 01/05/2026
Director of Finance/CFO 64 01/04/2024
Chief Tech/Sci/R&D Officer 51 11/09/2023
Director TitleAgeSince
Director/Board Member 60 30/04/2019
Director/Board Member 57 28/04/2020
Director/Board Member 64 28/04/2020
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+2.70% - - 104B
+1.86%+0.48%+55.50%+163.08% 1,082B
+3.57%+3.29%+68.60%+61.03% 633B
+3.99%+3.05%+37.93%+93.37% 461B
+3.86%+1.64%+32.57%+24.89% 338B
-0.56%+0.96%+41.67%+39.35% 299B
-0.08%+1.30%+32.15%+44.48% 291B
-1.54%+2.81%-25.35%-39.61% 222B
+3.55%+4.41%+25.45%+66.28% 202B
+4.21%+2.65%+17.47%+71.11% 163B
Average +1.89%+4.58%+31.78%+58.22% 410.27B
Weighted average by Cap. +2.18%+5.53%+42.31%+83.31%

Financials

2026 *2027 *
Net sales 47.12B 53.9B 43.3B 40.36B 76.55B 5,132B 77.71B 520B 202B 2,522B 202B 198B 8,692B 50.06B 57.26B 46B 42.88B 81.33B 5,452B 82.56B 552B 215B 2,680B 215B 210B 9,235B
Net income 8.4B 9.61B 7.72B 7.2B 13.66B 915B 13.86B 92.73B 36.05B 450B 36.09B 35.31B 1,551B 9.3B 10.64B 8.55B 7.97B 15.12B 1,013B 15.34B 103B 39.9B 498B 39.94B 39.09B 1,716B
Net Debt 9.67B 11.07B 8.89B 8.29B 15.72B 1,054B 15.95B 107B 41.49B 518B 41.53B 40.64B 1,785B 5.86B 6.7B 5.38B 5.02B 9.52B 638B 9.66B 64.64B 25.13B 314B 25.16B 24.62B 1,081B
Logo Sanofi
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (81.8%): prescription drugs for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases; - human vaccines (18.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2025, the group had 37 production sites worldwide. Net sales are distributed geographically as follows: France (3.9%), Europe (17.1%), the United States (50.8%), China (6%) and other (22.2%).
Employees
74,846
Date Price Change
03/07/26 €11.40 0.00%
02/07/26 €11.40 0.00%
01/07/26 €11.40 +0.88%
30/06/26 €11.30 0.00%
29/06/26 €11.30 +1.80%
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
75.81EUR
Average target price
96.70EUR
Spread / Average Target
+27.56%

Quarterly revenue - Rate of surprise